Advertisement
Australia markets closed
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • AUD/USD

    0.6609
    -0.0012 (-0.19%)
     
  • OIL

    79.85
    +0.59 (+0.74%)
     
  • GOLD

    2,379.40
    +39.10 (+1.67%)
     
  • Bitcoin AUD

    95,332.91
    +3,051.41 (+3.31%)
     
  • CMC Crypto 200

    1,303.58
    -54.43 (-4.01%)
     
  • AUD/EUR

    0.6130
    -0.0008 (-0.13%)
     
  • AUD/NZD

    1.0984
    +0.0015 (+0.14%)
     
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NASDAQ

    18,113.46
    +28.46 (+0.16%)
     
  • FTSE

    8,441.06
    +59.71 (+0.71%)
     
  • Dow Jones

    39,387.76
    +331.36 (+0.85%)
     
  • DAX

    18,782.25
    +95.65 (+0.51%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Most smaller biotech companies would love to follow in the footsteps of Vertex Pharmaceuticals (NASDAQ: VRTX). Let's turn to a smaller biotech that Vertex knows very well: CRISPR Therapeutics (NASDAQ: CRSP). The two companies are partners in a blood disorders program and recently submitted their treatment candidate for regulatory approval.